Global Licensing

 
News Articles for Global Licensing top ^
BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) , a global biopharmaceutical company, and Takeda Pharmaceutical Company Limited (Takeda) today announced that on October 17, 2014, they entered into a global license, development, commercialization and supply agreement for AMITIZA ® (lubiprostone). Through this agreement, Takeda expanded its exclusive rights beyond the United States (U.S.) and Canada to further develop and commercialize AMITIZA in all global markets, except Japan and the People's Republic of China.
Sign-up for Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone) investment picks
LONDON and RICHARDSON, Texas, Nov.
Sign-up for Michael Kors and Fossil Group Renew Global Licensing Agreement for Watches and Jewelry investment picks
2014/10/7
Two classic brands collaborate to create the sweet taste of success.
Sign-up for Hasbro and PEZ International Strike Sweet Global Licensing Deal for My Little Pony Branded PEZ Dispensers and Candy Line investment picks
Aratana to Develop CRTH2 Antagonist for Atopic Dermatitis in Companion Animals KANSAS CITY, Kan.
Sign-up for Aratana Therapeutics and Atopix Complete Global Licensing Agreement for Development and Commercialization of Novel Atopic Dermatitis Program investment picks
VALENCIA, Calif., Sept.
Sign-up for MannKind Announces Closing of Global Licensing Agreement With Sanofi investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Global Licensing
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Global Leadership  |  Next: Global Life